Lytgobi vs Pemazyre: Side-by-Side Comparison
Quick answer: Lytgobi and Pemazyre are both fgfr tyrosine kinase inhibitor used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Lytgobi | Pemazyre |
|---|---|---|
| Drug class | FGFR tyrosine kinase inhibitor | FGFR tyrosine kinase inhibitor |
| ATC code | L01EN03 | L01EN02 |
| Primary indications | Cholangiocarcinoma with FGFR2 fusions/rearrangements | Cholangiocarcinoma with FGFR2 fusion/rearrangement, Myeloid/lymphoid neoplasms with FGFR1 rearrangement |
| Mechanism | Irreversible inhibitor of fibroblast growth factor receptors (FGFR1-4) blocking tumor cell proliferation in FGFR-altered cancers | Selective inhibitor of fibroblast growth factor receptors 1-3 (pemigatinib) blocking aberrant FGFR signaling in tumors |
| Common dose | futibatinib 20 mg orally once daily | 13.5 mg once daily for 14 days of each 21-day cycle |
| Detail page | Lytgobi details → | Pemazyre details → |
How to choose between Lytgobi and Pemazyre
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All FGFR tyrosine kinase inhibitor on iMedic · Lytgobi full details · Pemazyre full details
Frequently asked questions
Is Lytgobi better than Pemazyre?
Neither is universally 'better.' They are both fgfr tyrosine kinase inhibitor with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Lytgobi to Pemazyre?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Lytgobi and Pemazyre have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Lytgobi and Pemazyre available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.